Responses
Research Article
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Compose a Response to This Article
Other responses
No responses have been published for this article.